Myostatin and markers of bone metabolism in dermatomyositis

Abstract Background In dermatomyostis (DM) patients, inflammation, reduced activity, and medication have a negative impact on the musculoskeletal system. Several endocrine factors are involved in muscle growth bone turnover. Objective: We aimed to investigate regulating myogenesis metabolism evaluate possible associations between these factors, strength, functional tests DM patients. Methods conducted cross-sectional study 20 dermatomyositis Serum levels of myostatin (MSTN), follistatin (FSTN), dickkopf 1 (Dkk1), sclerostin (SOST), periostin (PSTN), receptor activator nuclear factor kB ligand (RANKL):osteoprotegerin (OPG) ratio fibroblast 23 (FGF23) were determined. Physical function was evaluated by hand-held strength measurement, chair rising test, timed up go test 3-min walking test. Results MSTN FGF23 (2.5 [1.9; 3.2] vs. 1.9 [1.6; 2.3] 2.17 [1.45; 3.26] 1.28 [0.79; 1.96], respectively; p < 0.05) significantly higher patients than controls. Dkk1 lower (11.4 [6.9; 20.0] 31.8 [14.3; 50.6], 0.01). Muscle physical correlated with each other (e.g. hip flexion – test: r = ? 0.748, Conclusion biochemical musculo-skeletal markers altered shows deficits. All reflect independent different deficits long-term which is important for assessment as well planning therapeutic interventions clinical routine.